Ayala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report published on Friday. The brokerage issued a sell rating on the stock.

Ayala Pharmaceuticals Price Performance

Ayala Pharmaceuticals stock opened at $0.03 on Friday. The stock has a market capitalization of $1.15 million, a PE ratio of 0.00 and a beta of 1.70. The business has a 50 day simple moving average of $0.04 and a 200-day simple moving average of $0.08. Ayala Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $1.49.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.